Permanent Chemicals Linked to Aggressive Breast Cancer Rates
Exposure to specific per- and polyfluoroalkyl substances increases the risk of developing estrogen receptor-negative breast cancer, with perfluorooctanoic acid tied to a 63 percent rise and perfluorooctane sulfonate linked to a 93 percent jump, based on research published in the Journal of Clinical Oncology.
The study measured 17 different PFAS compounds in blood samples drawn from patients years before they received a breast cancer diagnosis. Scientists compared those samples against blood taken from women who never developed the disease. The analysis isolated two main chemicals: perfluorooctanoic acid, commonly found in nonstick cookware and certain food-contact materials, and perfluorooctane sulfonate, historically used in firefighting foams and waterproof textiles.
Blood Concentration Comparisons in Patient Samples
Women carrying higher blood concentrations of perfluorooctanoic acid faced a 67 percent higher risk of developing estrogen receptor-negative breast cancer compared to participants with low or undetectable levels of the substance. For perfluorooctane sulfonate, the risk increase reached 93 percent for the same aggressive tumor type. Study authors noted in an official communiqué that these percentages describe relative differences between tested groups rather than an individual woman’s overall chance of developing the disease.
These results are important for the health of women in general,
said Dr. Che-Jung Chang, lead author of the study. Although the PFAS persist in the environment and in our organism, the exposure to these substances is potentially modifiable. It is possible to take measures to reduce it, and these discoveries could open new perspectives in terms of prevention.
Biological Pathways Beyond Hormones
Because estrogen receptor-negative breast cancer produces non-hormone-dependent malignant tumors, researchers suggest the implicated forever chemicals influence disease risk through non-hormonal biological pathways. That influence likely operates through modifications to gene activity or alterations within the immune system, though the team did not test those specific mechanisms during the project and recommends further investigation to clarify the exact cellular interactions.
Regulatory pressures have largely phased out perfluorooctanoic acid and perfluorooctane sulfonate due to mounting environmental and health concerns, prompting manufacturers to introduce newer replacement PFAS compounds that remain less studied by the scientific community. Alexandra White, who led the research team, emphasized the need to evaluate cancer risks associated with these newer chemical alternatives.
Related reading